Purple Biotech (PPBT) Expected to Release Earnings on Friday

Purple Biotech (NASDAQ:PPBT) is expected to be posting its results before the market opens on Friday, November 13th. Analysts expect Purple Biotech to post earnings of ($2.88) per share for the quarter.

Purple Biotech Stock Performance

Shares of PPBT opened at $1.49 on Thursday. The stock has a 50-day moving average of $1.41 and a two-hundred day moving average of $2.84. The stock has a market cap of $1.38 million, a P/E ratio of -0.06 and a beta of 0.77. Purple Biotech has a one year low of $0.91 and a one year high of $8.90.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a research note on Thursday, October 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Purple Biotech presently has an average rating of “Hold” and a consensus target price of $30.00.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments. Purple Biotech’s pipeline has included CM24, a humanized monoclonal antibody targeting CEACAM1, an immune checkpoint involved in tumor-immune interactions. The company has evaluated CM24 in combination with other cancer therapies, including immune checkpoint inhibitors, for advanced solid tumors such as metastatic pancreatic cancer.